ES
MARKETS / NYSE / ABBV
NYSE · PHARMACEUTICAL PREPARATIONS · LARGE CAP

AbbVie Inc. ABBV

15 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY11 YEARS OF DIVIDEND GROWTH
Revenue · FY2025
$61.2B
▲ 8.6% vs FY2024
Dividend streak
11 yrs
Raised every year since 2015
EPS · FY25
$2.36
Dividend / sh · FY25
$6.65
Payout · FY25
276%
ROE · FY25
15367.3%
Net margin · FY25
6.9%
Dividend coverage
0.4×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 61.2B
Revenue, FY2025 · full 15-year series below
Revenue Net income
2040608061.24.2201120142017202020232025
2040608061.24.22016201920222025

7 cents of every revenue dollar became profit this year.

Per share
USD 2.36
Diluted EPS, FY2025
EPS Dividend
2.557.56.652.36201120142017202020232025
2.557.56.652.362016201920222025

Earnings covered only a fraction of the dividend — the rest came from cash or borrowing.

Profitability
15367.3%
Return on equity, FY2025
ROE
40008000120001600015367.3%201120142017202020232025
40008000120001600015367.3%2016201920222025
Operating margin24.6%
Net margin6.9%
Return on assets3.1%

Each USD of equity produced 15367 cents of profit this year.

Returned to shareholders
USD 12.5B
returned in FY2025 · dividends + net buybacks
Dividends paidUSD 11.7B
Net buybacksUSD 808.0M
Share of profit295.0%
Consecutive raises11 years

USD 11.7B in dividends and USD 808.0M in buybacks — 295% of the year's profit, so the payout drew on cash built up earlier.

Growth
+6.0% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+1.8%
+6.0%
+10.3%
Net income
−29.1%
−1.7%
−1.9%
EPS, diluted
−29.1%
−2.8%
−2.8%
Dividend / share
+5.2%
+6.6%
+12.2%
Returned to shareholders
+3.4%
+8.0%
+1.5%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—

A share split breaks the comparison across the period, so we leave it out.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 134.0B
total assets, end of FY2025
Total assetsUSD 134.0B
EquityUSD -3.3B
CashUSD 5.2B
Gross debtUSD 67.0B
Net debtUSD 61.8B
Current ratio0.67×

Net debt stands at -1889% of equity.

History
15 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
Revenue $B
61.2
56.3
54.3
58.1
56.2
45.8
33.3
32.8
28.2
25.6
22.9
20.0
18.8
18.4
17.4
Operating income $B
15.1
9.1
12.8
18.1
17.9
11.4
13.0
6.4
9.5
9.3
7.5
3.4
5.7
5.8
3.6
EBITDA $B
15.8
9.9
13.5
18.9
18.7
12.0
13.4
6.9
10.0
9.8
8.0
3.8
6.1
6.3
4.1
Income tax $B
2.4
−0.6
1.4
1.6
1.4
−1.2
0.5
−0.5
2.4
1.9
1.5
0.6
1.2
0.5
0.2
Net income $B
4.2
4.3
4.9
11.8
11.5
4.6
7.9
5.7
5.3
6.0
5.1
1.8
4.1
5.3
3.4
EPS, diluted $
2.36
2.39
2.72
6.63
6.45
2.72
5.28
3.66
3.30
3.63
3.13
1.10
2.56
3.35
2.18
Dividend / sh $
6.65
6.29
5.99
5.71
5.31
4.84
4.39
3.95
2.63
2.35
2.10
1.75
2.00
·
·
Payout %
276
258
217
85
80
167
81
98
77
62
64
150
62
·
·
ROE %
15367.3
62.5
35.2
72.5
81.0
188.3
·
·
109.1
138.7
180.9
56.9
199.3
·
·
Shares out B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
43 of 43
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed